Evaluating Women With Ovarian Cancer for BRCA1 and BRCA2 Mutations
- 1 May 2010
- journal article
- Published by Wolters Kluwer Health in Obstetrics & Gynecology
- Vol. 115 (5), 945-952
- https://doi.org/10.1097/aog.0b013e3181da08d7
Abstract
To estimate the incidence of genetic counseling referral for ovarian cancer patients who are at substantial risk for a BRCA1 or BRCA2 mutation. An analysis was performed of new ovarian cancer patients who were seen at a comprehensive cancer center from January 1, 1999, through December 31, 2007. Patients at substantial (more than 20-25%) risk for a BRCA1 or BRCA2 mutation were identified and records reviewed for referral to genetic counseling. Time to referral was estimated using the Kaplan-Meier method. A total of 3,765 epithelial ovarian cancer patients were seen during the 9-year period. On average, 23.8% of patients met substantial-risk criteria for BRCA mutations. In 1999, only 12% of patients at substantial-risk were referred. Referral improved over time with 48% referred in 2007 (P<.001). Newly diagnosed patients were more often referred for genetic counseling than new patients with recurrent disease or those seen as second opinions. African-American women meeting substantial-risk criteria were less likely to be referred than were white or Hispanic women (P=.009). Although dictated family history was accurate, interpretation of risk for BRCA1 or BRCA2 mutations and subsequent referral to genetic counseling was poor. Although there was significant improvement over time, 50% of substantial-risk patients still were missed. Systematic efforts to identify those ovarian cancer patients at substantial risk for a BRCA1 or BRCA2 are necessary.Keywords
This publication has 30 references indexed in Scilit:
- What women with ovarian cancer think and know about genetic testingGynecologic Oncology, 2008
- Society of Gynecologic Oncologists Education Committee Statement on Risk Assessment for Inherited Gynecologic Cancer Predispositions☆Gynecologic Oncology, 2007
- Who Should Be Sent for Genetic Testing in Hereditary Colorectal Cancer Syndromes?Journal of Clinical Oncology, 2007
- The Role of Financial Factors in Acceptance of Clinical BRCA Genetic TestingGenetic Testing, 2007
- Improved survival in BRCA2 carriers with ovarian cancerFamilial Cancer, 2006
- ASCO/SSO Review of Current Role of Risk-Reducing Surgery in Common Hereditary Cancer SyndromesJournal of Clinical Oncology, 2006
- BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma casesCancer, 2005
- Effect of BRCA Mutations on the Length of Survival in Epithelial Ovarian TumorsJournal of Clinical Oncology, 2002
- Prevalence and Penetrance of Germline BRCA1 and BRCA2 Mutations in a Population Series of 649 Women with Ovarian CancerAmerican Journal of Human Genetics, 2001
- Identification of the breast cancer susceptibility gene BRCA2Nature, 1995